Patients don’t ask “What’s the patent status?”—not really.
They ask something far more human: “Will this new drug actually work for me?” “Is it safe to switch?” “Will my insurance cover it?” “How long will I have to wait?” And increasingly, they’re tur…

Evergreening isn’t a rumor in pharma—it’s a playbook.
Brand teams don’t just defend a single patent. They stack continuations, tweak formulations, shift to new polymorphs, expand method-of-use claims, and—when the calendar gets tight—use “incremental” …

Pfizer’s Keytruda, also known as pembrolizumab, received initial FDA approval on September 4, 2014, for use in treating… https://www.Drugchatter.com/chat/37536/can-you-recall-the-initial-fda-approval-year-for-keytruda/

Patent cliffs don’t just erase revenue—they rewrite the competitive map.
When a blockbuster’s exclusivity window starts to close, the market doesn’t wait for you to catch up. Payers do not simply “react” to generic entry; they prepare for it. And the…

OpenAI’s GPT just took a swing at one of the most stubborn bottlenecks in pharma: the patent cliff.
DrugPatentWatch’s latest breakdown of OpenAI’s GPT–Rosalind work reads like a case study in what happens when generative AI stops being a “productivity …

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive moment isn’t when a generic launches—it’s when you didn’t see the challenge coming.
Paragraph IV drug patent challenges are oft…

Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s how to know exactly how long protection really lasts.
If you’re launching a product—or defending one—your timeline can’t be built on guesswork. In the GCC, “how long…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “innovating.” They’re extending. Here are 4 signals to watch.
If you’re in pharma, you already know the playbook: a competitor’s product starts to look less like a threat and more like a timeline. The patent clock ticks, the marke…